Core Viewpoint - The Manitoba Health Coalition and Ontario Health Coalition are responding to the deaths of two paid donors at for-profit plasma collection facilities owned by Grifols, raising concerns about safety and control of the blood system [1]. Group 1: Incident Response - The Coalitions have issued warnings regarding the safety of for-profit plasma collection and the implications for the blood system [1]. - Spokespeople will outline necessary questions and steps to enhance safety and restore confidence in the blood and plasma system following the incident [1]. Group 2: Event Details - A response event is scheduled for March 13 at 10:30 a.m. EDT / 9:30 a.m. CDT via Zoom, with registration required [2]. - Contact information for key representatives from the Manitoba and Ontario Health Coalitions is provided for further inquiries [3].

Core Insights - Indivior Pharmaceuticals is a key player in long-acting injectable treatments for opioid use disorder (OUD), focusing on evidence-based solutions like SUBLOCADE, which is a monthly injectable form of buprenorphine aimed at improving patient outcomes and reducing healthcare costs [1] - A recent study indicates that patients adhering to SUBLOCADE for 12 months experienced a 42% reduction in non-MOUD medical costs, supporting the company's strategy to evaluate OUD treatment based on total healthcare costs [1] Financial Performance - Indivior's stock (INDV) has a price-to-earnings (P/E) ratio of 18, reflecting investor confidence in its earnings potential [2] - The company faces financial challenges, indicated by a negative enterprise value to operating cash flow ratio of -207.20 and a debt-to-equity ratio of -3.58, suggesting potential difficulties in cash flow generation and financial structuring [2] - The current ratio of 0.71 indicates that Indivior may struggle to cover short-term liabilities with its short-term assets [3] Industry Position - Despite financial challenges, Indivior's focus on long-acting injectable treatments and evidence-based care positions it as a leader in addressing OUD, which is recognized as a chronic but treatable brain disease [3]

Financial Data and Key Metrics Changes - In Q4 2025, total investment income was $30 million, and net investment income was $11.6 million, down from $36.7 million and $15.7 million in Q3 2025 respectively [5][16] - The weighted average portfolio risk rating increased to 2.45 in Q4 2025 from 2.42 in Q3 2025 [16] - The total investment portfolio had a fair value of $927.4 million, a decrease of 2% from $946 million in Q3 2025 [16][20] - Net assets decreased to $484.9 million from $489.5 million at the end of Q3 2025 [20] - NAV per share was $13.42 at the end of Q4 2025, down 1% from $13.55 at the end of Q3 2025 [20] Business Line Data and Key Metrics Changes - The company completed 7 investments in new and existing portfolio companies totaling $42.9 million in Q4 2025 [5][14] - Notable investments included a $20 million investment in a mobility company and a $10 million investment in a special purpose vehicle for consumer products [14] Market Data and Key Metrics Changes - The company noted ongoing market volatility due to tariff uncertainty, interest rate policy changes, and geopolitical conflicts, impacting investment strategies [6] - The competitive landscape in software and consumer sectors is providing attractive returns, despite the company maintaining a conservative underwriting approach [30] Company Strategy and Development Direction - The company is focused on enhancing the risk profile of its portfolio through diversification and smaller position sizes [6] - The acquisition of SWK Holdings is expected to diversify the portfolio and strengthen capabilities in healthcare and life sciences [7][8] - The company aims to maintain a leverage ratio between 1.2 and 1.3 post-acquisition, considering economic conditions [34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in closing the SWK transaction, which is anticipated to stabilize the asset base and enhance earnings power [18][23] - The company expects to see attractive opportunities across technology, healthcare, and consumer sectors in the coming quarters [8][15] Other Important Information - Total operating expenses for Q4 2025 were $18.4 million, down from $21 million in Q3 2025 [19] - The company recorded a net realized loss on investments of $377 thousand in Q4 2025, compared to a loss of $1.3 million in Q3 2025 [19] Q&A Session Summary Question: Pipeline strength and industry focus - Management noted that the pipeline is stronger than the previous year, with significant contributions from BC Partners and SWK, indicating a positive outlook for new deals [29][30] Question: Pro forma leverage post-acquisition - The pro forma leverage post-SWK acquisition is expected to be just under 1.2, with a target range of 1.2 to 1.3 moving forward [34] Question: Updates on SWK Holdings portfolio - The SWK portfolio is expected to include 13 loans with a fair value of around $235 million, alongside equity positions [40] Question: Software portfolio performance - Management confirmed that Circadence has closed an equity round and signed a contract with the Department of Defense, indicating improved performance [43] Question: Share repurchase program - The company plans to revisit the share repurchase program post-acquisition, with discussions expected in May [51][52]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Corcept Therapeutics Incorporated during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Corcept common stock between October 31, 2024, and December 30, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 21, 2026 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Background - The lawsuit alleges that during the Class Period, Corcept's defendants misrepresented the strength of clinical trials supporting the New Drug Application (NDA) for relacorilant, claiming it was "powerful support" for FDA approval [5]. - Defendants communicated confidence in the NDA submission and indicated no anticipated obstacles to approval, despite the FDA raising concerns about the clinical evidence [5]. - The lawsuit claims that when the true situation regarding the NDA was revealed, investors suffered damages due to the misrepresentation [5].

Group 1 - BioSyent Inc. will report its financial results for Q4 and the full year ended December 31, 2025 on March 19, 2026 after market hours [1] - A presentation by René Goehrum, President and CEO, will be available on the company's website on the same date [1] - BioSyent is a profitable growth-oriented specialty healthcare company focused on acquiring or in-licensing, marketing, and distributing innovative pharmaceutical and oral health products [2] Group 2 - The company has 11,497,447 common shares outstanding as of the date of the press release [3] - For financial information and market quotes, the company directs to visit www.tmxmoney.com [3] - Contact information for further inquiries includes Mr. René C. Goehrum, President and CEO, with an email and phone number provided [4]

Group 1 - BioSyent Inc. will report its financial results for Q4 and the full year ended December 31, 2025 on March 19, 2026 after market hours [1] - A presentation by René Goehrum, President and CEO, will be available on the company's website on the same date [1] - BioSyent is a profitable growth-oriented specialty healthcare company focused on acquiring or in-licensing, marketing, and distributing innovative pharmaceutical and oral health products [2] Group 2 - The company has 11,497,447 common shares outstanding as of the date of the press release [3] - For financial information and market quotes, the company directs to visit www.tmxmoney.com [3] - Contact information for further inquiries includes Mr. René C. Goehrum, President and CEO, with an email and phone number provided [4]

Core Insights - Plus Therapeutics, Inc. is focused on developing precision diagnostics and radiopharmaceuticals for CNS cancers, with significant financial results and business highlights reported for Q4 2025 and the full year [1] Corporate Highlights - The company completed an upsized public offering generating $15 million in gross proceeds, extending its cash runway to support CNSide commercialization and two ongoing Phase 2 clinical programs [2] - The company secured an American Medical Association Category III CPT reimbursement code for REYOBIQ, enhancing market access for its therapy in recurrent glioblastoma and pediatric brain cancer [7] - CNSide laboratory licensing has expanded to 49 of 50 U.S. states, allowing access to the CNSide Tumor Cell Enumeration test for approximately 95% of the U.S. population [7] - The company recognized $5.2 million in grant revenue for 2025, compared to $5.8 million in 2024, primarily from CPRIT for REYOBIQ development [7] Financial Results - The company's cash and investments balance was $13.1 million on December 31, 2025, up from $3.6 million on December 31, 2024 [7] - Total operating loss for 2025 was $15.3 million, compared to $14.7 million in 2024, attributed to the expansion of the CNSide operations team [7] - Net loss for 2025 was $22.4 million, or $(0.29) per basic share, compared to a net loss of $13.0 million, or $(1.95) per basic share, in 2024 [7] Development and Clinical Programs - REYOBIQ is being evaluated for recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancer in ongoing clinical trials [12] - The company anticipates increased R&D expenditures in 2026 due to costs associated with the ReSPECT-LM clinical trial and manufacturing scale-up for REYOBIQ [9] - The company aims for CNSide Diagnostics to breakeven by 2027, with expected increases in general and administrative expenditures in 2026 [10] Future Milestones - The company plans to define the optimal dose for REYOBIQ in the ReSPECT-LM Phase 2 trial, with data expected in Q3 2026 [15] - Enrollment in the ReSPECT-GBM Phase 2 trial is expected to be completed, with data anticipated in Q4 2026 [15] - The company aims to expand U.S. commercial payer coverage to over 150 million covered lives and achieve more than 1,250 annualized test orders [16]

Core Insights - The company is focused on the development of transcript-related projects, indicating a commitment to enhancing its offerings in this area [1] Group 1 - The company publishes thousands of quarterly earnings calls each quarter, showcasing its extensive coverage and growth in the transcript publishing sector [1]

Summary of Cadrenal Therapeutics Conference Call Company Overview - **Company**: Cadrenal Therapeutics (NasdaqCM: CVKD) - **Focus**: Development of CAD-1005, an IV solution for treating heparin-induced thrombocytopenia (HIT) and other potential indications Key Points Industry and Product Development - **Recent Development**: Cadrenal has in-licensed CAD-1005, previously known as VLX-1005, which is ready to move into phase III development [2] - **Phase II Completion**: CAD-1005 has completed phase II trials, showing promising results in reducing thrombotic events in patients with HIT [4][5] - **Mechanism of Action**: CAD-1005 works by inhibiting 12-lipoxygenase, addressing the underlying platelet activation in HIT, unlike existing therapies that only treat the symptoms [9][10] Clinical Insights - **Patient Context**: HIT occurs in patients undergoing cardiac surgery who receive heparin, leading to a paradoxical increase in blood clots due to an immune reaction [3][39] - **Safety Profile**: The drug has shown no extra bleeding in phase I and phase II trials, which is a critical concern for anticoagulants [13] - **Primary Endpoint for Phase III**: The primary endpoint will focus on the reduction of thrombotic events, with a therapy duration of 7-14 days [19][21] Regulatory and Market Position - **FDA Designations**: CAD-1005 has received Orphan Drug status and Fast Track designation from the FDA, indicating a significant unmet medical need [5][18] - **Market Potential**: The estimated market for CAD-1005 is projected to be around $850 million in the U.S. and EU for HIT, which has not seen a new drug for decades [37] Future Directions - **Phase III Trial Design**: The trial will include a powered superiority analysis against placebo and will involve academic centers experienced in treating HIT [27][19] - **Funding Strategy**: The phase III program is estimated to cost between $35-$40 million and is expected to last about 24 months [36] - **Long-term Vision**: Success for Cadrenal includes submitting a New Drug Application (NDA) within three years and advancing their oral series, CAD-2000, into phase III for chronic indications like type 1 and type 2 diabetes [44][45] Additional Indications - **Potential Uses Beyond HIT**: CAD-1005 may also be effective in treating obesity and type 1 and type 2 diabetes, with ongoing research to explore these applications [10][42][43] Conclusion - **Strategic Focus**: Cadrenal is concentrating on HIT as the primary indication while also exploring other potential uses for CAD-1005, aiming for a strong market entry and subsequent expansion into other therapeutic areas [41][45]

Core Insights - Erasca, Inc. has observed encouraging early clinical activity for its RAS-targeting drug ERAS-0015, with ongoing responses in multiple RAS-mutant tumors and favorable safety and pharmacokinetics [1][2][3] - The company successfully completed an upsized financing round, raising approximately $259 million, which strengthens its financial position and supports operations into the second half of 2028 [1][4] - Phase 1 monotherapy data for ERAS-0015 is expected in the first half of 2026, while data for ERAS-4001 is anticipated in the second half of 2026 [1][2] Research and Development Highlights - Promising early clinical data for ERAS-0015 includes confirmed partial responses in multiple tumor types with different RAS mutations, showing no dose-limiting toxicities and predominantly low-grade adverse events [3] - The company is advancing its RAS-targeting franchise rapidly, with high enthusiasm from investigators and patients [2] Corporate Highlights - Erasca expanded its licensing agreement with Joyo Pharmatech to include China, Hong Kong, and Macau, granting worldwide rights to ERAS-0015 [4] - The U.S. Patent and Trademark Office issued patents for the RAS-targeting franchise, protecting the composition of matter for ERAS-4001 until June 2043 and for ERAS-0015 until September 2043 [4] Financial Results - As of December 31, 2025, Erasca reported cash, cash equivalents, and marketable securities of $341.8 million, down from $440.5 million in 2024, but expects to fund operations into the second half of 2028 [7][15] - R&D expenses decreased to $23.2 million for Q4 2025 from $26.1 million in Q4 2024, and for the full year, R&D expenses were $92.9 million compared to $115.4 million in 2024 [8] - The net loss for Q4 2025 was $29.1 million, or $(0.10) per share, compared to a net loss of $32.2 million, or $(0.11) per share, in Q4 2024 [10][18]